Why Pfizer's talking about breaking up on the same day it announced a $160 billion merger
This is not as crazy as it sounds. Investors have been pushing Pfizer to split off parts of the business for years.
In 2013, the company spun off its animal health arm, Zoetis, and it has promised more.
Now, the purchase of Allergan, whose most famous drug is Botox but which also produces other dermatology treatments and eye care drugs, Pfizer could be putting itself in the right place to actually see the breakup through.
What could emerge is two companies, analysts at Moody's explained. An innovative pharmaceutical company focused on research and development and an "established" pharmaceutical company that looks after Pfizer's drugs that have gone off patent like arthritis treatment Celebrex and cholesterol drug Lipitor. These still generate cash flow, but they're no longer blockbusters thanks to competition from generics.
Allergan fits into that picture: Allergan and the $2 billion in annual revenue that Botox brings in will boost the established products business. So the deal actually makes the split more practical.
And Allergan's pipeline will also help Pfizer's "innovative" side. Here's a breakdown of the areas Allergan is researching, including central nervous system and gastrointestinal treatments.
Pfizer
"The Allergan acquisition increases the likelihood that Pfizer will eventually split," Moody's analysts wrote. "While the acquisition likely pushes out the point at which Pfizer will consider splitting its pharmaceutical business, the split remains on the table."
What might frustrate investors too is Pfizer's declaration today that a spin-off deal wouldn't happen before 2018.
If that were to happen, Pfizer would by no means be the first to pull this off.
In 2013, Abbott Laboratories split off AbbVie as its biopharmaceutical arm focused on innovation. Baxter pulled the same stunt, spinning off Baxalta. And companies such as Novartis have, on a smaller scale, spun off three of its pipeline drugs into the biotech company Mereo BioPharma.
If the deal makes its way past shareholders and regulators, and if it doesn't run into too much trouble from politicians and government groups that have already begun to express their concerns over the merger, the Allergan-Pfizer combination could be official by the second half of 2016.
This leaves about a year and a half for Pfizer to decide if it's ready to break up.
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- A centenarian who starts her day with gentle exercise and loves walks shares 5 longevity tips, including staying single
- 2 states where home prices are falling because there are too many houses and not enough buyers
- Election Commission issues notification for sixth phase of Lok Sabha polls
- 6 Coffee recipes you should try this summer
- "To sit and talk in the box...!" Kohli's message to critics as RCB wrecks GT in IPL Match 45
- 7 Nutritious and flavourful tiffin ideas to pack for school
- India's e-commerce market set to skyrocket as the country's digital economy surges to USD 1 Trillion by 2030